Sunday, February 9, 2025

CATEGORY

Daiichi Sankyo

ENHERTU® Marks First HER2 Therapy for U.S. Breast Cancer Patients Post-Endocrine Treatment

Key TakeawaysENHERTU® offers a new therapeutic avenue for patients with limited treatment options post-endocrine therapy. The significant improvement in progression-free survival suggests ENHERTU®...

FDA Recognizes New Therapy for Advanced EGFR-Mutated Lung Cancer

Key TakeawaysDatopotamab deruxtecan addresses a critical gap in treatment options for EGFR-mutated NSCLC patients. Early trial results indicate a substantial improvement in response...

Daiichi Sankyo Launches Phase 3 Study of VANFLYTA for Newly Diagnosed FLT3-ITD Negative AML

Key TakeawaysVANFLYTA may establish a new standard of care for FLT3-ITD negative AML patients. Successful outcomes could lead to expanded indications for FLT3...

Daiichi Sankyo Showcases Cutting-Edge Cancer Treatments at Major Conferences

Key TakeawaysDato-DXd shows promising efficacy in EGFR-mutated NSCLC, potentially offering a new treatment avenue for patients with limited options. ENHERTU demonstrates significant benefits...

ENHERTU Receives Conditional Approval in China for HER2 Mutant Lung Cancer Treatment

Key TakeawaysENHERTU (trastuzumab deruxtecan) has received conditional approval in China, providing the first targeted therapy for HER2 mutant metastatic non-small cell lung cancer...

Daiichi Sankyo Submits Application for ENHERTU in Japan for HER2 Low and Ultralow Breast Cancer

Key TakeawaysDaiichi Sankyo submits an sNDA for ENHERTU in Japan, targeting HER2 low and ultralow metastatic breast cancer. The submission is based on...

Acute Myeloid Leukemia Patients to Benefit from FLT3 LeukoStrat CDx Test Approval for Targeted VANFLYTA Therapy

Key TakeawaysAcute myeloid leukemia patients with FLT3-ITD mutations will benefit from the newly approved FLT3 LeukoStrat CDx test, allowing for personalized treatment with...

Breast Cancer Treatment Advances as Enhertu Receives Priority Review for HER2-Low and HER2-Ultralow Metastatic Patients

Key TakeawaysThe FDA has granted Priority Review to Enhertu for the treatment of HER2-low and HER2-ultralow metastatic breast cancer, based on positive results...

Enhertu Granted US Priority Review for HER2-Low Breast Cancer

Key TakeawaysEnhertu received Priority Review for HER2-low and HER2-ultralow metastatic breast cancer after endocrine therapy. Phase 3 trial showed Enhertu improved progression-free survival...

Hypercholesterolemia and Dyslipidemia Patients Show Significant LDL-C Reduction with Bempedoic Acid in Real-World MILOS Study

Key TakeawaysThe MILOS study demonstrated that bempedoic acid significantly reduced LDL-C levels by 30.3% over two years, improving cholesterol management in patients with...

Datopotamab Deruxtecan Fails to Achieve OS Benefit in Breast Cancer Trial, But Shows PFS Gains

Key TakeawaysDatopotamab deruxtecan (Dato-DXd) did not reach statistical significance for overall survival (OS) in the TROPION-Breast01 Phase III trial. The trial had previously...

Lung Cancer Breakthrough: Patritumab Deruxtecan Significantly Improves Progression-Free Survival in EGFR-Mutated Non-Small Cell Lung Cancer

Key TakeawaysThe HERTHENA-Lung02 phase 3 trial demonstrated that patritumab deruxtecan significantly improved progression-free survival (PFS) in patients with EGFR-mutated non-small cell lung cancer...

Computational Pathology-Based TROP2 Biomarker Predicts Better Outcomes in Non-Small Cell Lung Cancer Treatment

Key Takeaways:AstraZeneca's proprietary TROP2-QCS biomarker predicts improved outcomes for NSCLC patients treated with datopotamab deruxtecan. The biomarker-based analysis shows significantly greater progression-free survival...

Ifinatamab Deruxtecan Shows Promising Results in Small Cell Lung Cancer

Key Takeaways:Ifinatamab deruxtecan demonstrates an objective response rate (ORR) of 54.8% in small cell lung cancer patients. The 12 mg/kg dose is selected...

Breast Cancer Patients with HER2 Low or Ultralow Metastatic Disease Benefit from ENHERTU® Type II Variation Application, Validated by EMA

Breast cancer patients with unresectable or metastatic HER2 low or HER2 ultralow tumors may soon have access to a promising new treatment option. The...

Latest news